PT  - JOURNAL ARTICLE
AU  - Amaku, Marcos
AU  - Covas, Dimas Tadeu
AU  - Coutinho, Francisco Antonio Bezerra
AU  - Azevedo, Raymundo Soares
AU  - Massad, Eduardo
TI  - Modelling the impact of contact tracing of symptomatic individuals on the COVID-19 epidemic
AID  - 10.1101/2021.02.05.21251222
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.05.21251222
4099  - http://medrxiv.org/content/early/2021/02/08/2021.02.05.21251222.short
4100  - http://medrxiv.org/content/early/2021/02/08/2021.02.05.21251222.full
AB  - OBJECTIVES With declining numbers of COVID-19 cases in the State of São Paulo, Brazil, social distancing measures were gradually being lifted. The risk of an increase in the number of cases, however, cannot be overlooked. Even with the adoption of non-pharmaceutical interventions, such as restrictions on mass gatherings, wearing masks, and complete or partial closure of schools, other public health measures may help to control the epidemic. We aimed to evaluate the impact of the contact tracing of symptomatic individuals on the COVID-19 epidemic regardless of the use of diagnostic testing.METHODS We developed a mathematical model that includes isolation of symptomatic individuals and tracing of contacts to assess the effects of the contact tracing of symptomatic individuals on the COVID-19 epidemic in the State of São Paulo.RESULTS For a selection efficacy (proportion of isolated contacts who are infected) of 80%, cases and deaths may be reduced by 80% after 60 days when 5000 symptomatic individuals are isolated per day, each of them together with 10 contacts. On the other hand, for a selection efficacy of 20%, the number of cases and deaths may be reduced by approximately 40% and 50%, respectively, compared with the scenario in which no contact tracing strategy is performed.CONCLUSION Contact tracing of symptomatic individuals may be a potential alternative strategy when the number of diagnostic tests available is not sufficient for a massive testing strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by LIM01-HFMUSP, CNPq, FAPESP and Fundacao Butantan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval. Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data on COVID-19 cases and deaths are available from https://www.seade.gov.br/